WO2012072665A1 - Compositions comprenant de la pipampérone et des antagonistes/inhibiteurs de la recapture de la sérotonine - Google Patents

Compositions comprenant de la pipampérone et des antagonistes/inhibiteurs de la recapture de la sérotonine Download PDF

Info

Publication number
WO2012072665A1
WO2012072665A1 PCT/EP2011/071350 EP2011071350W WO2012072665A1 WO 2012072665 A1 WO2012072665 A1 WO 2012072665A1 EP 2011071350 W EP2011071350 W EP 2011071350W WO 2012072665 A1 WO2012072665 A1 WO 2012072665A1
Authority
WO
WIPO (PCT)
Prior art keywords
pipamperone
sari
disorder
trazodone
dose
Prior art date
Application number
PCT/EP2011/071350
Other languages
English (en)
Inventor
Erik Buntinx
Original Assignee
Pharmaneuroboost N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaneuroboost N.V. filed Critical Pharmaneuroboost N.V.
Publication of WO2012072665A1 publication Critical patent/WO2012072665A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • the invention relates to the field of neuropsychiatry. More specifically, the invention relates to compositions comprising pipamperone and at least one serotonin antagonist reuptake inhibitor (SARI) and the use of such compositions for the treatment of mental disorders characterized by emotion dysregulation.
  • SARI serotonin antagonist reuptake inhibitor
  • DSM-IV American Psychiatric Association, (1993 - ISBN 0 - 89042 - 061 - 0)
  • DSM-IV is the in the art well-known gold standard of such a categorical classification.
  • each category of mental disorder is a completely discrete entity with absolute boundaries dividing it from other mental disorders or from no mental disorder.
  • Individuals sharing a diagnosis are likely to be heterogeneous even in regard to the defining features of the diagnosis.
  • the categorical defined mental disorders mood and anxiety disorders are having an external and even internal variable co-incidence of symptoms concerning mood and anxiety.
  • Structural pathology e.g. amyloid plaques in Alzheimer Disease
  • etiology e.g. HIV Dementia
  • deviance from a physiological norm e.g. reduced cerebral blood flow
  • the underlying dysregulation of various neurotransmittor systems is the in the art used model for the explanation of the biological determinants of the clinical presentation of mental disturbances.
  • Mood disorders include major depressive disorder, bipolar disorder (combining episodes of both mania and depression) and dysthymia.
  • mood disorders are one of the most common mental illnesses in the general population. Approximately 8% of adults will experience major depression at some time in their lives, while approximately 1 % will experience bipolar disorder. Other studies have reported that between 3% and 6% of adults will experience dysthymia during their lifetime, and that between 0.6% and 1 % of adults will have a manic episode during their lifetime. Because of their high prevalence, economic cost, risk of suicide and loss of quality of life, mood disorders present a serious public health concern in society. Also, depression and mania cause significant distress and impairment in social, occupational, educational or other important areas of functioning.
  • Depression is a serious mood disorder which affects millions of people, while the number of people being diagnosed with depression has increased dramatically. There is no single known cause of depression. Rather, it likely results from a combination of genetic, biochemical, environmental, and psychological factors. Nevertheless, important neurotransmitters appear to be out of balance. In particular, serotonin signaling is affected in depressed patients. Hence, depression is treated with antidepressants which work to normalize neurotransmitters, notably serotonin and norepinephrine. Other antidepressants work on the neurotransmitter dopamine. Although it is found that these particular neurotransmitters are involved in regulating mood, it is uncertain of the exact ways in which they work.
  • Anxiety disorders are the most common of emotional disorders and affect more than 25 million Americans.
  • Anxiety disorder is a persistent fear of social or performance situations that might involve exposure to unfamiliar people or possible scrutiny by others. Many forms and symptoms may include: overwhelming feelings of panic and fear, uncontrollable obsessive thoughts, painful, intrusive memories, recurring nightmares, and even physical symptoms such as feeling sick to your stomach, "butterflies” in your stomach, heart pounding, startling easily, and muscle tension. This condition, which often remains undetected and untreated, undermines a person's ability to become self-sufficient and impedes efforts to reduce welfare costs through return-to-work programs.
  • Anxiety Disorders include panic disorder, phobias, obsessive-compulsive disorer (OCD), posttraumatic stress disorder (PTSD) and generalized anxiety disorder (GAD). If left untreated, anxiety disorders can have severe consequences resulting in avoidance behavior which may create problems by conflicting with job requirements, family obligations or other basic activities of daily living. Moreover, many people who suffer from an untreated anxiety disorder are prone to other psychological disorders, such as depression, and they have a greater tendency to abuse alcohol and other drugs. Their relationships with family members, friends and coworkers may become very strained, while their job performance may falter.
  • Obsessions are upsetting and irrational thoughts which keep reoccurring. They cause great anxiety, which cannot be controlled through reasoning.
  • Common obsessions include preoccupations with dirt or germs, nagging doubts, and a need to have things in a very particular order.
  • OCD obsessive-compulsive disorder
  • Examples include repeated hand washing, constant rechecking to satisfy doubts, and following rigid rules of order. Compulsive behaviour can be very disruptive to normal daily routines and social relationships.
  • mood and anxiety disorders have a major effect on economy. This effect is dual in nature - first, with the associated loss of productivity in the workplace due to absenteeism and diminished effectiveness; and second, with the high health care costs attributable to primary care visits, hospitalizations and medication. At the individual and family level, the loss of income and cost of medication create a strain on the family financial resources. Hence, mood and anxiety disorders have a major economic impact through associated health care costs as well as lost work productivity. Accordingly, there is a substantial need to diagnose and treat these disorders.
  • SRIs serotonin reuptake inhibitors
  • MEOIs monoamine oxidase inhibitors
  • TCAs tricyclic antidepressants
  • TeCAs tetracyclic antidepressants
  • SARIs SARIs
  • antidepressants Due to the specific action of each class of antidepressants, different benefits as well as different side effects are associated with the various classes. In general, all antidepressants influence to one extent or another various neural systems and pathways. In particular, antidepressants exert their therapeutic effect by influencing neurotransmission as well as neurotransmitters. Most prominently, antidepressants directly or indirectly modulate serotonergic, dopaminergic, adrenergic and glutaminergic systems. While it is believed that serotonergic modulation constitutes a main desired effect of antidepressants, modulation of the additional systems and pathways is thought to be of importance as well.
  • Modulation of each of the systems and pathways is achieved in different ways for the different classes of antidepressants.
  • MAOIs block the degradation of the monoamine neurotransmitters serotonin, norepinephrine, and dopamine by inhibiting the enzyme monoamine oxidase, leading to increased concentrations of these neurotransmitters in the brain and an increase in neurotransmission.
  • Other classes of antidepressants generally mediate neurotransmission by binding of the antidepressant to one or more of the cellular receptors for neurotransmitters which are involved in the respective neural pathways. Indeed, these classes of antidepressants can in fact be classified according to their receptor binding profile. For instance, the SRIs have the strongest affinity for the serotonin transporter (SERT). Binding of the antidepressant to SERT inhibits presynaptic serotonin reuptake and as a consequence leads to increased synaptic serotonin concentrations and an increase in neurotransmission.
  • SERT serotonin transporter
  • antidepressants While some antidepressants have a more narrow primary mode of action, generally, antidepressants are not exclusively specific for the intended targets, which may lead to off-target effects. In addition, even if reasonably specific, due to the complex interplay between various neural systems, including numerous feed-back mechanisms, most, if not all, antidepressants display a broad spectrum of physiological effects, including unintended and deleterious side effects. Commonly observed side effects for SRIs include for instance headache, nausea, insomnia, nervousness, agitation and sexual problems. Also the serotonin syndrome has been has been shown to result from the use of not only SRIs, but many types of antidepressants, including SARIs.
  • SARIs are a class of antidepressants which have binding affinities for various neurotransmitter receptors and transporters. SARIs have the strongest affinity for the 5-HT 2 A serotonin receptor and act as an antagonist of this receptor. SARIs also have a strong affinity for the 5-HT 1A serotonin receptor and act as a partial agonist of this receptor. In addition, SARIs have a low to moderate affinity for SERT and act as an inhibitor of this transporter. Due to their demonstrated affinity for SERT, initially, it had been postulated that SARIs act in a similar fashion as SRIs by inhibiting SERT, thereby increasing synaptic serotonin concentration and neurotransmission.
  • SARIs also have moderate to strong affinity for the a1 , a2 and/or H1 receptors, which in conjunction with the effects on 5-HT 2 A cumulatively exert hypnotic effects. Additional common side effects associated with SARIs include dizziness, lightheadedness, drowsiness, nausea and vomiting, nervousness, headache, dry mouth and blurred vision.
  • SARIs generally have a good safety profile and prompt relief of symptoms (Munozza, 2006, Current Medical Research and Opinions, 22: 1703-1713), for reasons of the above mentioned side effects of SARIs, these compounds are currently not often used as first line antidepressants. Rather, intolerability towards or ineffectiveness of other antidepressants may incite the use of SARIs. More often, SARIs are used as conjunctive therapy with other antidepressants, notably SRIs. In this respect, SARIs have been shown to function in augmenting SRI effectiveness.
  • the present inventor surprisingly found that the effects of SARIs may be further ameliorated when used in conjunction with a low dose of pipamperone. Accordingly, the present invention relates in particular to the subject-matter of the appended claims as presented herein.
  • the instruction leaflet from the manufacturer Janssen Cilag B.V details psychoses and the symptomatic treatment of serious forms of agitation and anxiety as the therapeutic indications for pipamperone.
  • the leaflet warns against the use of pipamperone in depression.
  • the recommended initial dose is 40 to 80 mg pipamperone a day. If necessary, it is recommended to increase the dose up to a maximum of 360 mg pipamperone per day.
  • pipamperon doses range between 0.1 and 20 mg. Due to this particularly low dose of pipamperone, the pharmacological properties, such as receptor binding profile, is not comparable anymore with the pharmacological properties at conventional doses.
  • WO 2005/053796 relates to low doses of antagonists of 5-HT2A and D4 receptors in order to augment the effects of these compounds in mental disorders, notably mood and axiety disorders.
  • One of these antagonists is pipamperone, which is active in the range of 5-15 mg per day for a broad class of compounds, notably SRIs.
  • SARIs Given the fact that the affinity for SERT is manifold (up to a 100 fold) lower than the affinity for the 5-HT 2 A and 5-HT 1A receptors, it has been postulated that the antidepressant mode of action of this class of antidepressants is mediated by the combined effects on the 5-HT 2 A and 5-HT 1A receptors (Marek, Psychopharmacology, 1992, 109:2-11).
  • SARIs are partial agonists of the 5-HT 1A receptor, thereby being directly linked to antidepressant activity.
  • activation of the 5-HT 2A receptor can function to provide a negative feed-back mechanism towards the 5- HT 1A receptor.
  • an increased serotonin concentration indiscriminately activates both the 5-HT 2A and 5-HT 1A receptors (as well as other serotonin receptors). While activation of the 5-HT 1A receptor initiates antidepressant activity, simultaneous activation of the 5-HT 2A receptor suppresses the 5-HT 1A receptor, thereby counteracting the antidepressant activity.
  • SARIs combine these two effects, antidepressant activity of these compounds has been attributed to the combined antagonistic and agonistic action on the 5-HT 2 A and 5-HT 1A receptor, respectively.
  • the strong affinity of SARIs for the 5-HT 2 A receptor has also been associated with many of the side effects of these drugs, notably the hypnotic-associated side effects.
  • the present inventor has contraintuitively and surprisingly found that a low dose of pipamperone, which in itself, even at the claimed low dose, also has a very strong affinity for the 5-HT 2 A receptor, can be combined with SARIs to provide a superior antidepressant effect, while at the same time, surprisingly, no concomitant increase in side effects is observed.
  • pipamperone is also a potent D4 dopamine receptor antagonist. Numerous feedback mechanisms and interplays have been described between serotonergic and dopaminergic pathways. For instance, 5-HT 2A antagonism, besides giving the above described des-inhibition of the inhibitory effect of the 5-HT 2A receptor on the 5-HT 1A receptor stimulation by serotonin (S. M.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising pipamperone in a dose between 0.1 and 20 mg (of the active ingredient) or a pharmaceutically acceptable salt thereof and at least one serotonin antagonist and reuptake inhibitor (SARI), or a pharmaceutically acceptable salt thereof, or a derivative thereof or an active metabolite thereof.
  • the composition comprises pipamperone in a dose between 5 and 15 mg.
  • said SARI in the composition is selected from the group consisting of trazodone, etoperidone, nefazodone, and lubazodone.
  • said SARI is trazodone, or a pharmaceutically acceptable salt thereof, or a derivative thereof or an active metabolite thereof.
  • the dose of said SARI is between 20 and 600 mg (of the active ingredient), preferably between 20 and 400 mg.
  • said pipamperone and said SARI are the sole pharmaceutically active ingredients in the composition.
  • said composition further comprises at least one pharmaceutically acceptable excipient.
  • At least said SARI is formulated for extended release.
  • the invention relates to a composition as described herein, for use in treating a disorder characterized by an underlying emotion dysregulation.
  • said disorder is selected from the group consisting of mood disorders and/or anxiety disorders.
  • said mood disorder is Major Depressive Disorder.
  • the composition is to be administered daily. In another embodiment, the composition is to be divided for multiple administrations per day.
  • pipamperone and said SARI are to be administered simultaneously or sequentially.
  • said SARI is to be administered at least one day after the onset of administration of said pipamperone.
  • the terms "one or more” or “at least one”, such as one or more or at least one member(s) of a group of members, is clear per se, by means of further exemplification, the term encompasses inter alia a reference to any one of said members, or to any two or more of said members, such as, e.g., any ⁇ 3, ⁇ 4, ⁇ 5, ⁇ 6 or ⁇ 7 etc. of said members, and up to all said members.
  • SARIs serotonin antagonists/reuptake inhibitors
  • a problem to be solved by the present invention is thus the provision of a more efficient therapy and efficient, highly selective and efficacious medicaments for treating mental disorders, in particular depression and anxiety.
  • the present inventor surprisingly found that pipamperone at a dose between 0.1 and 20 mg/day in combination with SARIs, in particular trazodone, etoperidone, nefazodone, and lubazodone, has an improved effect in treating mood and anxiety disorders. Contrary to the findings of the present inventor, it was expected that pipamperone would on the one hand not have a beneficial effect in combining with SARIs, and on the other hand might even exacerbate the unwanted side effects of SARIs.
  • the present inventor surprisingly found that a simultaneous or foregoing treatment with pipamperone having a high selective 5-HT 2 A and D4 receptor antagonist activity leads to a greater response towards SARIs.
  • the present inventor surprisingly found that pipamperone at a dose ranging between 0.1 and 20 mg/day in combination with SARIs, has an improved effect in treating mood and anxiety disorders, by an increased D4 and 5-HT 2 A receptor occupancy, while adverse effects are not increased or preferably absent.
  • the combination treatment and medicaments of the invention provides faster symptom resolution, less residual symptoms and/or more remission relative to a mono therapy with these compounds.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising pipamperone in a dose between 0.1 and 20 mg (of the active ingredient) or a pharmaceutically acceptable salt thereof and at least one serotonin antagonist and reuptake inhibitor (SARI), or a pharmaceutically acceptable salt thereof, or a derivative thereof or an active metabolite thereof.
  • said composition consists essentially of pipamperone in a dose between 0.1 and 20 mg (of the active ingredient) or a pharmaceutically acceptable salt thereof and at least one serotonin antagonist and reuptake inhibitor (SARI), or a pharmaceutically acceptable salt thereof, or a derivative thereof or an active metabolite thereof.
  • said composition consists of pipamperone in a dose between 0.1 and 20 mg (of the active ingredient) or a pharmaceutically acceptable salt thereof and at least one serotonin antagonist and reuptake inhibitor (SARI), or a pharmaceutically acceptable salt thereof, or a derivative thereof or an active metabolite thereof.
  • SARI serotonin antagonist and reuptake inhibitor
  • the term "consists essentially of” refers to a composition comprising only the referenced ingredients as (pharmaceutically) active compound. Accordingly, in an embodiment, the invention relates to a composition as described herein, wherein pipamperone in a dose between 0.1 and 20 mg (of the active ingredient) or a pharmaceutically acceptable salt thereof and at least one serotonin antagonist and reuptake inhibitor (SARI), or a pharmaceutically acceptable salt thereof, or a derivative thereof or an active metabolite thereof are the sole (pharmaceutically) active ingredients.
  • SARI serotonin antagonist and reuptake inhibitor
  • compositions as described herein comprise only one SARI.
  • pharmaceutical composition refers to a composition which can be used as a medecine.
  • a pharmaceutical composition is intended to be beneficial for the treatment of a particular disease or disorder. Therefore, a pharmaceutical composition is a non-toxic composition.
  • the composition may display unintended side effects when administered to a subject, such composition is nevertheless considered not to be toxic, due to the intended benefits attributed to the composition.
  • harmful side effects may occur, such as allergies towards one or more compounds within the composition. Such does not, however, preclude this composition as being generally (i.e. to the patient population as a whole) to be beneficial and non-toxic.
  • the term "derivative" refers to a compound which is derived from another compound by chemical modification of said other compound. Preferably, said derivative has the same activity or substantially the same activity as the compound from which it is derived from.
  • active metabolite refers to a catabolic breakdown product of a specific compound which still displays a pharmacological activity.
  • said metabolite has the same activity or substantially the same activity as the compound from which it is a metabolite of.
  • the invention relates to a composition as described herein, for use in treating a disorder characterized by an underlying emotion dysregulation.
  • said disorder is selected from the group consisting of mood disorders and/or anxiety disorders.
  • said mood disorder is Major Depressive Disorder.
  • the invention relates to the use of a composition as described herein, for treating a disorder characterized by an underlying emotion dysregulation.
  • said disorder is selected from the group consisting of mood disorders and/or anxiety disorders.
  • said mood disorder is Major Depressive Disorder.
  • the invention relates to the use of a composition as described herein, for the manufacture of a medicament for treating a disorder characterized by an underlying emotion dysregulation.
  • said disorder is selected from the group consisting of mood disorders and/or anxiety disorders.
  • said mood disorder is Major Depressive Disorder.
  • the invention relates to a method for treating a disorder characterized by an underlying emotion dysregulation, comprising administering a composition as described herein.
  • said disorder is selected from the group consisting of mood disorders and/or anxiety disorders.
  • said mood disorder is Major Depressive Disorder.
  • DSM-IV-TR Diagnostic and Statistical Manual of Mental Disorders
  • ICD-10 the WHO'S International Statistical Classification of Diseases and Related Health Problems
  • the mood disorders grouped under the DSM-IV include major depressive disorder, dysthymic disorder, bipolar disorder, cyclothymic disorder, mood disorder due to a general medical condition and substance induced mood disorder. For each of these mood disorders there are specific criteria that a person's symptoms must meet in order to receive a diagnosis.
  • the anxiety disorders grouped under the DSM-IV include panic disorder, phobias, obsessive-compulsive disorder (OCD), posttraumatic stress disorder (PTSD) and generalized anxiety disorder (GAD). For each of these anxiety disorders there are specific criteria that a person's symptoms must meet in order to receive a diagnosis.
  • depression includes Major depressive disorder, Major depressive episode, Atypical depression, Melancholic depression, Psychotic depression, Depressive Disorder Not Otherwise Specified, Depression (mood), Postpartum depression, Dysthymia, Adjustment disorder with depressed mood, Seasonal affective disorder (SAD), all as known in the art.
  • Depression can be scored by e.g. the Hamilton Depression Rating Scale (HDRS or HAMD) (Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 196023:56-62) or the Montgomery-Asberg Depression Rating Scale (abbreviated MADRS). There is, however, a high degree of statistical correlation between scores on the two measures.
  • the Clinical Global Impression (CGI) rating scales are commonly used measures of symptom severity, treatment response and the efficacy of treatments in treatment studies of patients with mental disorders.
  • the CGI - Severity scale (CGI-S) is a 7-point scale which can be used by the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis.
  • Pipamperone is the conventional name given for the compound of the formula T-[3-(p- Fluorobenzoyl)propyl]-[1 ,4'-bipiperidine]-4'-carboxamide. Pipamperone is also the active ingredient of for instance the commercially available Dipiperon (Janssen, Cilag B.V).
  • the therapeutic indications for pipamperone are psychoses and the symptomatic treatment of serious forms of agitation and anxiety only.
  • Pipamperone is contraindicated for depression.
  • the active ingredient is available in tablets of 40 mg per tablet or in solutions of 2 mg per drop.
  • Conventional usage of high doses ranging from 40 to 360 mg is prescribed. For instance, for children up to the age of 14, doses corresponding with 2 to 6 mg per kg body weight are conventionally prescribed.
  • compositions as described herein comprise pipamperone, or a pharmaceutically acceptable salt thereof, in a dose between (about) 0.1 and 20 mg per day, preferably between (about) 5 and 15 mg
  • compositions as described herein comprise pipamperone, or a pharmaceutically acceptable salt thereof, in a dose of (about) 0.1 , 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1 , 1.1 , 1.2, 1.3, 1.4, 1.5, 1.6,
  • the listed doses and dose ranges of pipamperone are for daily administration. Accordingly, in an aspect, the daily dose of pipamperone in the compositions as described herein for the treatment of mood and anxiety disorders, such as depression is as listed above.
  • pipamperone doses at the lower end of the dose range may be preferred for the treatment of mood and anxiety disorders in children and elderly patients. Accordingly, in an embodiment, doses up to about 15 mg, preferably up to about 10 mg, more preferable up to about 5 mg are to be administered daily to children or elderly patients for the treatment of mood and anxiety disorders.
  • doses within the claimed dose range, may be varied for the treatment of mood and anxiety disorders depending on the body weight of the patient. Accordingly, in an embodiment, doses between (about) 0.05 and 0.25 mg per kg body weight are to be administered daily for the treatment of mood and anxiety disorders, such as for instance (about) 0.05, 0.06, 0.07, 0.08, 0.09, 0.1 , 0.1 1 , 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.21 , 0.22, 0.23, 0.24, and 0.25 mg per kg body weight.
  • SARI serotonin antagonist reuptake inhibitor
  • SARI refers to compounds which act by antagonizing serotonin receptors such as 5-HT 2 A and inhibiting the reuptake of serotonin, norepinephrine, and/or dopamine.
  • SARI does not exclude the effects of these compounds on any other compound, e.g. other neurotransmitters.
  • SARI antidepressants include trazodone, etoperidone, nefazodone, and lubazodone, or a derivative thereof or an active metabolite thereof. Affinities (Kd in nM) of several SARIs for different receptors and transporters are listed in Table 1. The selected compounds act as antagonists at all receptors listed except at 5-HT 1A where they are partial agonists, and as inhibitors of all transporters listed.
  • compositions as described herein comprise at least one SARI, preferably selected from the group consisting of trazodone, etoperidone, nefazodone, and lubazodone in a dose between (about) 20 mg and (about) 600 mg.
  • the compositions as described herein comprise at least one SARI , preferably selected from the group consisting of trazodone, etoperidone, nefazodone, and lubazodone in a dose between (about) 20 mg and (about) 400 mg.
  • the dose of SARI is (about) 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 1 10, 1 15, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 4
  • the listed doses and dose ranges of SARI are for daily administration. Accordingly, in an aspect, the daily dose of SARI in the compositions as described herein for the treatment of mood and anxiety disorders, such as depression is as listed above.
  • composition as described herein comprises more than one SARI
  • the dose of each SARI can be as listed above. More preferably, f the composition as described herein comprises more than one SARI , the total dose SARI added up is as listed above.
  • SARI doses at the lower end of the dose range may be preferred for the treatment of mood and anxiety disorders in children and elderly patients.
  • doses within the claimed dose range, may be varied for the treatment of mood and anxiety disorders depending on the body weight of the patient. Accordingly, in an embodiment, doses between (about) 0.25 and 10 mg per kg body weight are to be administered daily for the treatment of mood and anxiety disorders, such as for instance (about) 0.25, 0.5, 0.75, 1, 1 .25, 1.5, 1 .75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75, 5, 5.25, 5.5, 5.75, 6, 6.25, 6.5, 6.75, 7, 7.25, 7.5, 7.75, 8, 8.25, 8.5, 8.75, 9, 9.25, 9.5, 9.75, 10 mg per kg body weight.
  • Trazodone (l UPAC name 2-(3-[4-(3-chlorophenyl)piperazin-1 -yl]propyl)-[1 ,2,4]triazolo[4,3- a]pyridin-3(2/-/)-one) is marketed under the names Desyrel, Oleptro, Beneficat, Deprax, Desirel, Molipaxin, Thombran, Trazorel, Trialodine, Trittico and Mesyrel. Trazodone was originally developed by Angelini research laboratories (US3381009, incorporated herein by reference in its entirety).
  • the present invention relates to compositions comprising pipamperone in the claimed dose range and trazodone or a pharmaceutically acceptable salt thereof, or a derivative thereof, or an active metabolite thereof. It will be appreciated by the skilled person that combinations of pipamperone with any of the marketed trazodone formulations are specific embodiments of the present invention.
  • Preferred daily trazodone doses are between 20 and 600 mg, such as between 20 and 500 mg, between 20 and 400 mg, preferably between 20 and 300 mg, more preferably between 20 and 200 mg, even more preferable between 20 and 150 mg, most preferably between 20 and 100 mg. It is to be understood that these doses are unitary doses, and may be divided over several fractional doses per day. In an embodiment, the dose is between 0.5 and 5 mg/kg body weight, such as 0.5, 1 , 1.5, 2, 2.5, 3, 3.5, 4, 4.5 or 5 mg/kg body weight.
  • daily trazodone doses, or doses of pharmaceutically acceptable salts thereof or doses of derivatives or active metabolites thereof are between 100 and 600 mg, such as between 100 and 500, between 100 and 400, between 100 and 300, between 100 and 200, between 150 and 600, between 150 and 500, between 150 and 400, between 150 and 300, between 150 and 200, between 200 and 600, between 200 and 500, between 200 and 400, or between 200 and 300 mg.
  • derivatives of trazodone can be used.
  • Preferred derivatives have Formula I.
  • R is hydrogen or methyl; and wherein R' is a member selected from the group consisting of hydrogen, lower alkyl having 1 to 4 carbon atoms, lower alkoxy having 1 to 4 carbon atoms, and halogen.
  • said derivative is a pharmaceutically acceptable salt of a compound with Formula I, preferably a salt with an organic or inorganic acid.
  • R, R', R", and R'" is a lower alkyl having 1 to 3 carbon atoms.
  • said derivative is a pharmaceutically acceptable salt of a compound with Formula II, preferably a salt with an organic or inorganic acid.
  • a person skilled in the art will appreciate that compounds having a combination of Formula I and II are also preferred compounds in embodiments according to the invention.
  • Nefazodone (lUPAC name 1-(3-[4-(3-chlorophenyl)piperazin-1-yl]propyl)-3-ethyl-4-(2- phenoxyethyl)-1 /-/-1 ,2,4-triazol-5(4/-/)-one) is marketed under the names Serzone and Nefadar. Nefazodone was originally developed by Mead Johnson & Company (US4338317, incorporated herein by reference in its entirety). In a preferred embodiment, the present invention relates to compositions comprising pipamperone in the claimed dose range and trazodone or a pharmaceutically acceptable salt thereof, or a derivative thereof, or an active metabolite thereof. It will be appreciated by the skilled person that combinations of pipamperone with any of the marketed nefazodone formulations are specific embodiments of the present invention.
  • Preferred daily nafazodone doses are between 20 and 600 mg, such as between 20 and 500 mg, between 20 and 400 mg, preferably between 20 and 300 mg, more preferably between 20 and 200 mg, even more preferable between 20 and 150 mg, most preferably between 20 and 100 mg. It is to be understood that these doses are unitary doses, and may be divided over several fractional doses per day. In an embodiment, the dose is between 0.5 and 5 mg/kg body weight, such as 0.5, 1 , 1.5, 2, 2.5, 3, 3.5, 4, 4.5, or 5 mg/kg body weight.
  • daily trazodone doses, or doses of pharmaceutically acceptable salts thereof or doses of derivatives or active metabolites thereof are between 100 and 600 mg, such as between 100 and 500, between 100 and 400, between 100 and 300, between 100 and 200, between 150 and 600, between 150 and 500, between 150 and 400, between 150 and 300, between 150 and 200, between 200 and 600, between 200 and 500, between 200 and 400, or between 200 and 300 mg.
  • derivatives of trazodone can be used.
  • Preferred derivatives have Formula III.
  • R is halogen.
  • said derivative is a pharmaceutically acceptable salt of a compound with Formula III, preferably a salt with an organic or inorganic acid.
  • Hydroxynefazodone has Formula IV
  • (R-)hydroxynefazodone is a pharmaceutically acceptable salt of a compound with Formula IV, preferably a salt with an organic or inorganic acid.
  • a person skilled in the art will appreciate that compounds having a combination of Formula III and IV are also preferred compounds in embodiments according to the invention.
  • Etoperidone (lUPAC name 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-4,5-diethyl-1 ,2,4- triazol-3-one) is marketed under the name Axiomin, Depracer, Etonin, Etoran, Staff, and Tropene. Etoperidone is also known as clopradone and thozalinone. Etoperidone was originally developed by Angelini research laboratories (US3857845, incorporated herein by reference in its entirety).
  • the present invention relates to compositions comprising pipamperone in the claimed dose range and etoperidone or a pharmaceutically acceptable salt thereof, or a derivative thereof, or an active metabolite thereof.
  • etoperidone or a pharmaceutically acceptable salt thereof, or a derivative thereof, or an active metabolite thereof.
  • Preferred daily etoperidone doses, or doses of pharmaceutically acceptable salts thereof or doses of derivatives or active metabolites thereof are between 20 and 600 mg, such as between 20 and 500 mg, between 20 and 400 mg, preferably between 20 and 300 mg, more preferably between 20 and 200 mg, even more preferable between 20 and 150 mg, most preferably between 20 and 100 mg.
  • doses are unitary doses, and may be divided over several fractional doses per day.
  • the dose is between 0.5 and 5 mg/kg body weight, such as 0.5, 1 , 1.5, 2, 2.5, 3, 3.5, 4, 4.5, or 5 mg/kg body weight.
  • daily etoperidone doses, or doses of pharmaceutically acceptable salts thereof or doses of derivatives or active metabolites thereof are between 100 and 600 mg, such as between 100 and 500, between 100 and 400, between 100 and 300, between 100 and 200, between 150 and 600, between 150 and 500, between 150 and 400, between 150 and 300, between 150 and 200, between 200 and 600, between 200 and 500, between 200 and 400, or between 200 and 300 mg.
  • Lubazodone (lUPAC name (2S)-2-[(7-fluoro-2,3-dihydro-1 H-inden-4-yl)oxymethyl]- morpholine) is also known as YM-992, YM-35,995.
  • the present invention relates to compositions comprising pipamperone in the claimed dose range and lubazodone or a pharmaceutically acceptable salt thereof, or a derivative thereof, or an active metabolite thereof.
  • Preferred daily lubazodone doses are between 20 and 600 mg, such as between 20 and 500 mg, between 20 and 400 mg, preferably between 20 and 300 mg, more preferably between 20 and 200 mg, even more preferable between 20 and 150 mg, most preferably between 20 and 100 mg. It is to be understood that these doses are unitary doses, and may be divided over several fractional doses per day. In an embodiment, the dose is between 0.5 and 5 mg/kg body weight, such as 0.5, 1 , 1.5, 2, 2.5, 3, 3.5, 4, 4.5, or 5 mg/kg body weight.
  • daily lubazodone doses, or doses of pharmaceutically acceptable salts thereof or doses of derivatives or active metabolites thereof are between 100 and 600 mg, such as between 100 and 500, between 100 and 400, between 100 and 300, between 100 and 200, between 150 and 600, between 150 and 500, between 150 and 400, between 150 and 300, between 150 and 200, between 200 and 600, between 200 and 500, between 200 and 400, or between 200 and 300 mg.
  • derivatives of lubazodone can be used.
  • Preferred derivatives have Formula V or VI (a levorotary optical isomer of V).
  • R and R" may be the same or different, each represent hydrogen or a lower alkyl group; R' represents a halogen atom; the dotted line indicates an optional double bond.
  • said derivative is a pharmaceutically acceptable salt of a compound with Formula V or VI, preferably a salt with an organic or inorganic acid.
  • the dose of the SARIs as described herein for treating patients with mental disorders may be decreased to about 10 - 90% of the conventional dose, preferably to about 20 - 80%, or 30 - 70%, or 40 - 60% or to about 50% of the conventional dose. Even if the administered dose of the SARI is decreased in the combination therapy, the therapeutic effect may be sustained or ameliorated relative to the conventional dose. The danger of side effects of a treatment with SARIs, can be decreased or minimized in the combination therapy of the invention.
  • the term conventional dose refers to the dose used contemporaneously for SARIs, in particular trazodone, etoperidone, nefazodone, and lubazodone, for the treatment of mood disorders and anxiety disorders, for instance, according to the supplier's or physician's description.
  • treatment include amelioration or elimination of a developed mental disease or condition, in particular depression, once it has been established or alleviation of the characteristic symptoms of such disease or condition.
  • these terms also encompass, depending on the condition of the patient, preventing the onset of depression or of symptoms associated with depression, including reducing the severity of depression or symptoms associated therewith prior to affliction with said depression.
  • Such prevention or reduction prior to affliction refers to administration of the compound or composition of the invention to a patient that is not at the time of administration afflicted with depression.
  • Preventing also encompasses preventing the recurrence or relapse-prevention of depression or of symptoms associated therewith, for instance after a period of improvement.
  • treating also includes prevention of a physical disease or condition or amelioration or elimination of the developed physical disease or condition once it has been established or alleviation of the characteristic symptoms of such conditions.
  • the term “medicament” also encompasses the terms “drug”, “therapeutic”, “potion” or other terms which are used in the field of medicine to indicate a preparation with therapeutic or prophylactic effect.
  • the invention relates to compositions of pipamperone for use in treating mood disorders or anxiety disorders, and in particular depression whereby pipamperone is administered simultaneously with or sequential to said SARIs, in particular trazodone, etoperidone, nefazodone, and lubazodone, to augment the therapeutic effect of said SARIs in the treatment of mood disorders and anxiety disorders, and in particular depression, or to provide a faster onset of the therapeutic effect of said SARIs in the treatment of said mood disorders and anxiety disorders, and in particular depression.
  • SARIs in particular trazodone, etoperidone, nefazodone, and lubazodone
  • pipamperone when pipamperone is administered prior to the SARIs as disclosed herein, pipamperone is administered at least during 1 day prior to the onset of said SARI administration. Preferably, pipamperone is administered for at least 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13 or 14 days prior to the administration of said SARI. Preferably, pipamperone is administered for at least 2, 3, 4 or 5 weeks prior to the administration of said SARI.
  • pipamperone and the SARIs as disclosed herein are administered within 24 hours, e.g. on the same day, even more preferably within 16 hours, or even more preferably within 14, 12, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 hour, or even less.
  • pipamperone is administered at the same time or substantially the same time as the SARI as disclosed herein.
  • Pipamperone and SARIs are preferably administered once a day.
  • the compounds are administered 2, or 3 or even 4 times a day.
  • the present invention also contemplates depot injection, controlled release, extended release or slow release formulations, in which a long acting form of the active compound is injected into the body, such as the muscles. From there the active compound slowly enters the rest of the body, so one injection can last from 1 to 4 weeks or even multiple months.
  • Other form of dosage administrations relate to "once-a- week" pills, in which the ingredient is slowly released over a period of a week, and slow- release patches, e.g.
  • At least the SARI, optionally also pipamperone are formulated as a controlled release composition, a slow release composition or and extended release composition.
  • the SARI, preferably trazodone, or a pharmaceutically acceptable salt thereof, or a derivative thereof or an active metabolite thereof and optionally also pipamperone are formulated for once a day administration as extended release.
  • Suitable (preferred) formulations are disclosed in WO2007048219 (preferably for trazodone), WO2007048220 (preferably for trazodone), US6607748 (preferably for trazodone), US7829120 (preferably for trazodone), and US6143325 (preferably for nefazodone) the content of which is incorporated herein in its entirety.
  • pipamperone per day of any dosage regime is as described above, e.g. from about 0.1 mg per day to about 20 mg pipamperone per day.
  • pipamperone and SARIs may be present a single composition or in separate compositions.
  • the compositions according to the invention may be pharmaceutical compositions or formulations. If present in separate compositions, pipamperone and the SARIs may be administered simultaneously of sequentially.
  • said pipamperone and said SARI are administered in separate pharmaceutical compositions or formulations.
  • Said separate pharmaceutical compositions or formulations of either pipamperone or SARI can be individually packed.
  • said separate pharmaceutical compositions or formulations are packed together, i.e. combined preparations, such as, for instance, in one box, on one strip, e.g. blister strip, etc.
  • Said separate pharmaceutical compositions or formulations are preferred in adjusting individual doses of either or both compounds, within the ranges of the invention.
  • the invention relates to combined preparations comprising a pharmaceutical composition comprising pipamperone, and a pharmaceutical composition comprising a SARI as defined herein, for simultaneous, separate or sequential use for treating a mood disorder or anxiety disorder, wherein said pipamperone is to be administered to a patient in a daily dose ranging between 0.1 and 20 mg of the active ingredient.
  • said pipamperone and said SARI are administered in separate pharmaceutical compositions or formulations, or in pharmaceutical compositions or formulations comprising both elements, such as, for instance, combination pharmaceutical compositions or combination formulations.
  • said combination is a pill, powder or solution comprising both pipamperone and said SARI at the doses of the invention, for ease in administration and management.
  • the low dose pipamperone augments the therapeutic effect of and/or provides a faster onset of SARIs, in particular trazodone, etoperidone, nefazodone, and lubazodone, or a pharmaceutically acceptable salt thereof, or a derivative thereof or an active metabolite thereof in the treatment of mood disorders, such as depression, or anxiety disorders.
  • the combination treatment of the present invention provides at least a similar therapeutic effect with lower doses of SARIs as described herein, relative to the conventional doses of said SARIs.
  • the amount of pipamperone required to produce the efficacious effect will, of course, vary and is ultimately at the discretion of the medical practitioner.
  • the factors to be considered include the route of administration and nature of the formulation, the patient's body weight, age and general condition and the nature and severity of the disease to be treated.
  • Patient packs containing the whole course of treatment in a single package, usually a blister pack.
  • Patient packs have an advantage over traditional prescriptions, where a pharmacist divides a patient's supply of a pharmaceutical from a bulk supply, in that the patient always has access to the package insert contained in the patient pack, normally missing in traditional prescriptions.
  • the inclusion of a package insert has been shown to improve the patient's compliance with the physician's instructions.
  • a patient pack comprising at least one active ingredient of the combination of the invention and an information insert containing directions on the use of the combination of the invention.
  • the invention provides a double pack comprising in association for separate administration of either pipamperone or a SARI as disclosed herein.
  • the compounds according to the invention may be chemical or biological in nature, or may be chemically synthesised.
  • the term "antagonist” refers to an interaction between chemicals in which one partially or completely inhibits the effect of the other, in particular agents having high affinity for a given receptor, but which do not activate this receptor.
  • the term “inverse agonist” refers to a ligand which produces an effect opposite to that of the agonist by occupying the same receptor.
  • the term “agonist” relates to an agent which both binds to a receptor and has an intrinsic effect.
  • the term “partial agonist” relates to an agent with lower intrinsic activity than a full agonist, and which produces a lower maximum effect.
  • active metabolite as used herein relates to a therapeutically active compound produced by the metabolism of a parent drug.
  • Drugs administered to treat diseases are usually transformed (metabolized) within the body into a variety of related chemical forms (metabolites), some of which may have therapeutic activity (an active metabolite).
  • a particularly preferred active metabolite of the SARIs as disclosed herein in mCPP metal- Chlorophenylpiperazine; lUPAC name 1-(3-chlorophenyl)piperazine.
  • mCPP is a common active metabolite of trazodone, nefazodone and etoperidone, and is a non-selective serotonin receptor agonist and serotonin releasing agent. It has been suggested that it may play a role in for instance trazodone's therapeutic benefits.
  • compositions comprising pipamperone and SARIs, in particular trazodone, etoperidone, nefazodone, and lubazodone, administered in the form of a pharmaceutically acceptable salt in admixture with a suitable pharmaceutically acceptable excipient.
  • compositions comprising pipamperone and SARIs, in particular trazodone, etoperidone, nefazodone, and lubazodone
  • an effective amount of the active ingredients in acid or base addition salt form or base form, is combined in admixture with a pharmaceutically acceptable carrier, which can take a wide variety of forms depending on the form of preparation desired for administration.
  • a pharmaceutically acceptable carrier which can take a wide variety of forms depending on the form of preparation desired for administration.
  • These pharmaceutical compositions are desirably in unitary dosage form suitable, for administration orally, nasal, rectally, percutaneously, transdermal ⁇ , by parenteral, intramuscular, intravascular injection or intrathecal administration.
  • any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed.
  • the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
  • the pharmaceutical compounds for treatment are intended for parenteral, topical, oral or local administration and generally comprise a pharmaceutically acceptable carrier and an amount of the active ingredient sufficient to reverse or prevent the bad effects of mental disorders.
  • the carrier may be any of those conventionally used and is limited only by chemico-physical considerations, such as solubility and lack of reactivity with the compound, and by the route of administration.
  • the compounds of the invention are provided as a pharmaceutically acceptable salt.
  • pharmaceutically acceptable acid addition salts for use in the present inventive pharmaceutical composition include those derived from mineral acids, such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric and sulfuric acids, and organic acids, such as tartaric, acetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic, succinic, p-toluenesulphonic acids, and arylsulphonic, for example.
  • the present invention relates specifically to pipamperone and the use thereof, characterised in that said pipamperone is pipamperone dihydrochloride or pipamperone acetate.
  • a preferred salt of the SARIs according to an embodiment of the invention is a hydrochloric acid salt. Accordingly, in a preferred embodiment, trazodone, etoperidone, nefazodone, and lubazodone is provided in the compositions according to the invention as trazodone, etoperidone, nefazodone, and lubazodone hydrochloride. Trazodone hydrochloride is disclosed in EP1108722 and WO2009019133, the content of which are incorporated herein by reference in its entirety. Nefazodone hydrochloride is disclosed in US6448404 , the content of which are incorporated herein by reference in its entirety.
  • Another preferred salt of the SARIs according to an embodiment of the invention is a methane sulphonate salt.
  • trazodone, etoperidone, nefazodone, and lubazodone is provided in the compositions according to the invention as trazodone, etoperidone, nefazodone, and lubazodone methane sulphonate.
  • Nefazodone methane sulphonate is disclosed in US6034085, the content of which are incorporated herein by reference in its entirety. This salt of nefazodone is particularly useful in extended release formulations.
  • pharmaceutically acceptable excipients described herein for example, vehicles, adjuvants, carriers or diluents, are well-known to those who are skilled in the art and are readily available to the public. It is preferred that the pharmaceutically acceptable carrier be one that is chemically inert to the active compounds and one that has no detrimental side effects or toxicity under the conditions of use.
  • parenteral compositions for oral, aerosol, parenteral, subcutaneous, intravenous, intramuscular, interperitoneal, rectal, and vaginal administration are merely exemplary and are in no way limiting.
  • requirements for effective pharmaceutical carriers for parenteral compositions are well known to those of ordinary skill in the art. See Pharmaceutics and Pharmacy Practice, J.B. Lippincott Company, Philadelphia, PA, Banker and Chalmers, eds., pages 238-250, (1982), and ASHP Handbook on Injectable Drugs, Toissel, 4th ed., pages 622-630 (1986).
  • Topical formulations including those that are useful for transdermal drug release, are well-known to those of skill in the art and are suitable in the context of the present invention for application to skin.
  • Formulations comprising pipamperone and SARIs, in particular trazodone, etoperidone, nefazodone, and lubazodone, suitable for oral administration require extra considerations considering the nature of the compounds and the possible breakdown thereof if such compounds are administered orally without protecting them from the digestive secretions of the gastrointestinal tract.
  • Such a formulation can consist of (a) liquid solutions, such as an effective amount of the compound dissolved in diluents, such as water, saline, or orange juice; (b) capsules, sachets, tablets, lozenges, and troches, each containing a predetermined amount of the active ingredient, as solids or granules; (c) powders; (d) suspensions in an appropriate liquid; and (e) suitable emulsions.
  • Liquid formulations may include diluents, such as water and alcohols, for example, ethanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent, or emulsifying agent.
  • Capsule forms can be of the ordinary hard- or soft-shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers, such as lactose, sucrose, calcium phosphate, and corn starch.
  • Tablet forms can include one or more of lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, microcrystalline cellulose, acacia, gelatin, guar gum, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, calcium stearate, zinc stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, disintegrating agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible excipients.
  • Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to the active ingredient, such excipients as are known in the art.
  • a flavor usually sucrose and acacia or tragacanth
  • pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to the active ingredient, such excipients as are known in the art.
  • the compounds of the present invention i.e. pipamperone and SARIs, in particular trazodone, etoperidone, nefazodone, and lubazodone, in combination with other suitable components, can be made into aerosol formulations to be administered via inhalation.
  • the compounds are preferably supplied in finely divided form along with a surfactant and propellant. Typical percentages of compounds are 0.01 %-20% by weight, preferably 1 %-10%.
  • the surfactant must, of course, be nontoxic, and preferably soluble in the propellant.
  • esters or partial esters of fatty acids containing from 6 to 22 carbon atoms such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride.
  • Mixed esters, such as mixed or natural glycerides may be employed.
  • the surfactant may constitute 0.1 %-20% by weight of the compounds, preferably 0.25-5%.
  • the balance of the compounds is ordinarily propellant.
  • a carrier can also be included as desired, e.g., lecithin for intranasal delivery.
  • aerosol formulations can be placed into acceptable pressurized propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. They also may be formulated as pharmaceuticals for non-pressured preparations, such as in a nebulizer or an atomizer. Such spray formulations may be used to spray mucosa. It should be clear that the compounds and compositions described herein are useful for treating any patient in need thereof, in particular humans.
  • Patients receiving antidepressant monotherapy may be or become partially or totally resistant to treatment in 10 to 30 percent of cases. "Pooping-out” can occur with any conventional antidepressant. Relapse or recurrence of depression while still taking medication (i.e., breakthrough) can also occur. While there is no definitive answer as to why this happens, it may be a case of the patient developing tolerance to the drug.
  • the most commonly strategies used to deal with this problem include augmentation with a second drug, raising the dose or switching to another drug entirely.
  • a change from one antidepressant to another in the same or different class has not produced impressive response rates among depressed patients. If drug-switching is chosen as the method of therapy, patients should be closely monitored for possible drug interactions or other adverse effects. This is particularly true if the half-life of the first agent is quite long (e.g., fluoxetine [Prozac]) and another drug is begun before a prudent "wash- out” period has occurred. This situation may sometimes result in serotonin syndrome (toxic levels of central nervous system serotonin that result in hyperalertness, agitation, confusion, restlessness, myoclonus, hyperreflexia, diaphoresis, shivering, tremor and, possibly, death).
  • serotonin syndrome toxic levels of central nervous system serotonin that result in hyperalertness, agitation, confusion, restlessness, myoclonus, hyperreflexia, diaphoresis, shivering, tremor and, possibly, death).
  • pipamperone in combination with a SARI as disclosed herein also show an improved effect on treatment refractory patients with mood disorders or anxiety disorders. Because of high specific binding affinity, pipamperone can be used at low doses. At these low doses, adverse effects are minimized and/or precluded (see e.g. WO2005053796, which is herein incorporated by reference in its entirety).
  • the present invention relates to the use as described herein, characterised in that the pharmaceutical composition is for treatment of patients who have failed to respond to initial treatment with an antidepressant and/or anxiolytic agent, including a SARI or SRI. More in particular, the present invention relates to compositions as described above, characterised in that the pharmaceutical composition is for treatment of patients with major depression disorder who have failed to respond to initial treatment with an antidepressant or anxiolytic agent, including a SARI or SRI. Accordingly, the present invention relates to the compositions as described herein, characterised in that the pharmaceutical composition is for treatment of treatment refractory patients to an antidepressant or anxiolytic agent, including a SARI or SRI. More in particular, the present invention relates to the compositions as described herein, characterised in that the pharmaceutical composition is for treatment of major depression in treatment refractory patients to an antidepressant or anxiolytic agent, including a SARI or SRI.
  • treatment refractory patient is used as common in the art, such as, for instance, as understood by the clinician or physician monitoring and/or treating a patient. This term includes patients who have failed to respond to initial treatment, patients who are partially or totally resistant to treatment, patients with recurrent mood or anxiety disorder, and patients pooping-out. Patients who have failed to respond to initial treatment, include patients not ameliorating after for instance 2 weeks of treatment, as diagnosed by criteria described above.
  • SRIs serotonin re-uptake inhibitors
  • SSRIs selective serotonin reuptake inhibitors
  • SNDRIs serotonin noradrenalin dopamine reuptake inhibitors
  • SNRIs serotonin noradrenalin reuptake inhibitors
  • mood and/or anxiety disorders can be treated with compositions comprising pipamperone and SARIs.
  • the invention also relates to a composition as described herein, further comprising one or more SRI.
  • the present invention relates to a composition as described herein, further comprising an at least one SRI, for use in treating a disorder characterized by an underlying emotion dysregulation.
  • said disorder is selected from the group consisting of mood disorders and/or anxiety disorders.
  • said mood disorder is Major Depressive Disorder.
  • the invention relates to the use of a composition as described herein, further comprising at least one SRI, for treating a disorder characterized by an underlying emotion dysregulation.
  • said disorder is selected from the group consisting of mood disorders and/or anxiety disorders.
  • said mood disorder is Major Depressive Disorder.
  • the invention relates to the use of a composition as described herein, further comprising at least one SRI, for the manufacture of a medicament for treating a disorder characterized by an underlying emotion dysregulation.
  • said disorder is selected from the group consisting of mood disorders and/or anxiety disorders.
  • said mood disorder is Major Depressive Disorder.
  • the invention relates to a method for treating a disorder characterized by an underlying emotion dysregulation, comprising administering a composition as described herein, further comprising at least one SRI.
  • said disorder is selected from the group consisting of mood disorders and/or anxiety disorders.
  • said mood disorder is Major Depressive Disorder.
  • said SRI is an SSRI compound selected from the group consisting of citalopram, escitalopram, YM 992, VPI-013 (also known as OPC-14523), sertraline, paroxetine, LY 214.281 , LU AA 21-004, Lu 35-138, litoxetine, ifoxetine, fluvoxamine (controlled release formulation), fluvoxamine, fluoxetine, femoxetine, EMD 68843, cyanodothepine, cericlamine, ademethionine (preferably s-adenosylmethionine), milnacipran, venlafaxine, duloxetine and desvenlafaxine or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof.
  • said SSRI compound is chosen from the group consisting of citalopram, escitalopram, litoxetine and fluvoxamine (controlled release formulation), or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof.
  • said SSRI compound is citalopram and is to be administered in a daily dose ranging between 5 and 60 mg or between 20 and 40 mg of the active ingredient, such as 5, 7.5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55 or 60 mg; said SSRI compound is escitalopram and is to be administered in a daily dose ranging between 5 and 50 mg or between 12.5 and 25 mg of the active ingredient, such as 5, 7.5, 10, 12.5, 15, 17.5, 20, 25, 30, 35, 40, 45 or 50 mg; said SSRI compound is paroxetine and is to be administered in a daily dose ranging between 20 and 75 mg or between 25 and 60 mg of the active ingredient, such as 12.5, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70 or 75 mg; said SSRI compound is fluoxetine and is to be administered in a daily dose ranging between 20 and 60 mg or between 30 and 50 of the active ingredient, such as 20, 25, 30, 35, 40, 45, 50, 55 or 60 mg; said SSRI compound
  • the invention relates to a composition as described herein, further comprising an SSRI in a unitary dose as indicated above. It is to be understood that these doses are unitary doses, and may be divided over several fractional doses per day.
  • the SRI is citalopram (lUPAC name (f?S)-1- (3-dimethylaminopropyl)-1-(4-fluorofenyl)- 1 ,3-dihydroisobenzo- furaan-5-carbonitril) or its S-entantiomer escitalopram, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof.
  • said SRI is an SNRI compound selected from the group consisting of venlafaxine, tomoxetine, tandamine, talsupram, talopram, milnacipran, LY 113.821 , duloxetine, desvenlafaxine and amoxapine, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof.
  • said SNRI compound is chosen from the group consisting of venlafaxine, tomoxetine, milnacipran, duloxetine and desvenlafaxine, or a pro-drug or an active metabolite thereof, or a pharmaceutically acceptable salt thereof.
  • said SNRI compound is milnacipran and is to be administered in a daily dose ranging between 50 and 200 mg of the active ingredient; said SNRI compound is amoxapine and is to be administered in a daily dose ranging between 100 and 600 mg of the active ingredient, such as 100, 150, 200, 250, 300, 350, 400, 450, 500, 550 or 600 mg; said SNRI compound is venlafaxine and is to be administered in a daily dose ranging between 75 and 300 mg of the active ingredient; said SNRI compound is duloxetine and is to be administered in a daily dose ranging between 40 and 120 mg of the active ingredient; said SNRI compound is tomoxetine and is to be administered in a daily dose ranging between 0.475 and 3.8 mg/kg body weight of the active ingredient, such as 0.475, 0.95, 1.0, 1.2, 1.5, 1.75, 1.9, 2.0, 2.25, 2.5, 2.75, 3.0, 3.5 or 3.8 mg/kg; and said SNRI compound
  • the invention relates to a composition as described herein, further comprising an SSRI in a unitary dose as indicated above. It is to be understood that these doses are unitary doses, and may be divided over several fractional doses per day.
  • said SRI is an SNDRI compound selected from the group consisting of NS 2330; NS 2359, McN 5652; DOV 216,303 and DOV 21 ,947; more preferably NS 2359 or DOV 216,303; or a pro-drug or an active metabolite thereof; or a pharmaceutically acceptable salt thereof.
  • EXAMPLE 1 Foregoing pipamperone-trazodone treatment in major depressive disorder: a placebo and active controlled period finding clinical trial
  • Table 2 represents the set-up of a clinical trial comprising for treatment groups:
  • Group Pic - Active / Day 0 represents the group receiving 75 mg trazodone, twice a day, starting the first day (Day 0) of active treatment in the clinical trial. This administration regime is also indicated as the mono therapy.
  • Group Pip - Active / Day 0 represents the group receiving a combination of 5 mg pipamperone and 75 mg trazodone, twice a day, starting the first day (Day 0) of active treatment in the clinical trial. This administration regime is also indicated as the non- foregoing combo therapy.
  • Group Pip - Active / Day 4 represents the group receiving 5 mg pipamperone, twice a day, starting the first day (Day 0) of active treatment in the clinical trial, followed by a combination of 5 mg pipamperone and 75 mg trazodone, twice a day, starting the fifth (Day 4) day of active treatment in the clinical trial.
  • This administration regime is also indicated as the foregoing therapy with combination therapy starting after 4 days of active treatment.
  • Group Pip - Active / Day 7 represents the group receiving 5 mg pipamperon, twice a day, starting the first day (Day 0) of active treatment in the clinical trial, followed by a combination of 5 mg pipamperone and 75 mg trazodone, twice a day, starting the eight (Day 7) day of active treatment in the clinical trial.
  • This administration regime is also indicated as the foregoing therapy with combination therapy starting after 7 days of active treatment.
  • PLC placebo
  • Neuronal E-clinical Trial Vesalius Expert development for this trial which includes the bottom-up measurement of:
  • Pipamperone administered to patients in a dose ranging between 5 and 15 mg is claimed via its specific pharmacological properties to be a booster of the antidepressant effect of the SARI trazodone.
  • the mechanism of boosting of pipamperone has to deal with (i) the selective affinity for the dopamine-4 (D4) receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other dopamine receptors, and (ii) the selective affinity for the 5-HT 2 A receptor with a pKi value equal to or higher than 8 towards the 5-HT 2 A receptor and less than 8 towards other 5-HT receptors.
  • D4 dopamine-4
  • 5-HT 2 A receptor with a pKi value equal to or higher than 8 towards the 5-HT 2 A receptor and less than 8 towards other 5-HT receptors.
  • Patients have a major depressive disorder according to DSM-IV criteria, with or without a chronic course and a treatment refractory state towards another SARI or SRI than trazodone.
  • Pipamperone (Pip) and trazodone (Traz) dosage was adjusted according to clinical response.
  • PIP-TRAZ 1 fore-going 1-5 pipamperone from day 0 - trazodone from day 1-5
  • Pipamperone (Pip) and trazodone (Traz) dosage was adjusted according to clinical response.
  • PIP-TRAZ 1 fore-going 6-8 pipamperone from day 0 - trazodone from day 6-8
  • Trazodone 1 Traz: 100-300 mg/day
  • Pipamperone (Pip) and trazodone (Traz) dosage was adjusted according to clinical response.
  • Adverse events are assessed on: body as a whole, central and peripheral nervous system, gastrointestinal, musculoskeletal, psychiatric, respiratory, skin and appendages, vascular and urinary, taking into account discontinued treatment due to adverse events. Laboratory parameters, ECG, bodyweight and vital signs are not measured since this is a naturalistic study.
  • the combination pipamperone-trazodone is generally well tolerated in patients with depression i.e. at least no specific added adverse events are expected by adding pipamperone at the doses used in the study.
  • pipamperone 10 mg/day or an active antidepressant compound or the combination of the last two;
  • pipamperone 10 mg/day combined with and without an active antidepressant compound or an active antidepressant compound without pipamperone;
  • pipamperone 10 mg/day combined with an active antidepressant compound or an active antidepressant compound without pipamperone.
  • EXAMPLE 4 combo pipamperone-trazodone: therapeutic use in Obsessive- Compulsive Disorder (OCD).
  • Pipamperone (1 '-[3-(p-Fluorobenzoyl)propyl]-[1 ,4'-bipiperidine]-4'-carboxamide), the active ingredient of Dipiperon (Janssen-Cilag B.V), is administered to a patient in a dose ranging between 5 and 15 mg, is claimed via its specific pharmacological properties to be a booster of the effect of the SARI trazodone towards OCD.
  • the mechanism of boosting of pipamperone has to deal with (i) the selective affinity for the dopamine-4 (D4) receptor with a pKi value equal to or higher than 8 towards the D4 receptor and less than 8 towards other Dopamine receptors, and (ii) the selective affinity for the 5-HT 2 A receptor with a pKi value equal to or higher than 8 towards the 5- HT 2 A receptor and less than 8 towards other 5-HT receptors.
  • D4 dopamine-4
  • 5-HT 2 A receptor with a pKi value equal to or higher than 8 towards the 5- HT 2 A receptor and less than 8 towards other 5-HT receptors.
  • Medication Exclusion of mood stabilisers, antipsychotics (typical and atypical) and other antidepressants and anxiolytics
  • PIP-TRAZ ADD-ON trazodone from DAY minus 730-60 - pipamperone from DAY 0, in which Pipamperone (Pip) and Trazodone (Traz) dosage is adjusted according to clinical response.
  • PIP-TRAZ FORE-GOING 4-6 pipamperone from DAY 0 - trazodone from DAY 4-6, in which Pipamperone (Pip) and Trazodone (Traz) dosage is adjusted according to clinical response.
  • results are scored via Y-BOCS total score: "fore-going” and "add-on” treatment with pipamperone (5-15 mg/day) and trazodone (100-300 mg/day; bid) in comparison with the SSRI fluvoxamine in OCD.
  • Treatment with the combo pipamperone-trazodone (n 7).
  • Treatment with fluvoxamine (controlled release) mean 271 mg/day (n 253) is according to Hollander et al. (2003).
  • the intention-to-treat/last-observation-carried-forward analysis is evaluated relating to therapeutic efficacy according Y-BOCS total score, obsession and compulsion scores.
  • the boosting effect of pipamperone at an unconventional low dose on a SARI is studied relating to the efficacy of the 'add-on' and 'fore-going' combo 'pipamperone 5- 15 mg/day - trazodone 100-300 mg/day' in the treatment of patients with obsessive- compulsive disorder.
  • the combination pipamperone-trazodone is assessed in patients with OCD, no specific added adverse events are expected by adding pipamperone at the doses used in the study.
  • EXAMPLE 5 combo pipamperone-trazodone: therapeutic use in Panic Disorder.
  • PIP-TRAZ ADD-ON trazodone from DAY minus 24-2 months - pipamperone from DAY 0, in which Pipamperone (Pip) and Trazodone (Traz) dosage is adjusted according to clinical response.
  • PIP-TRAZ FORE-GOING 4-6 pipamperone from DAY 0 - trazodone from DAY 4-6, in which Pipamperone (Pip) and Trazodone (Traz) dosage is adjusted according to clinical response.
  • End Points Assessment scale scores CGI-severity score, Reduction, Remission Medication: Exclusion of mood stabilisers, antipsychotics (typical and atypical) and other antidepressants and anxiolytics Results
  • Treatment regimen A: PLC + PLC

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions comprenant de la pipampérone et un antagoniste/inhibiteur de la recapture de la sérotonine (AIRS), ainsi que l'utilisation de telles compositions pour le traitement des troubles de l'humeur et du trouble anxieux.
PCT/EP2011/071350 2010-11-30 2011-11-30 Compositions comprenant de la pipampérone et des antagonistes/inhibiteurs de la recapture de la sérotonine WO2012072665A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10193187.1 2010-11-30
EP10193187 2010-11-30

Publications (1)

Publication Number Publication Date
WO2012072665A1 true WO2012072665A1 (fr) 2012-06-07

Family

ID=45406677

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/071350 WO2012072665A1 (fr) 2010-11-30 2011-11-30 Compositions comprenant de la pipampérone et des antagonistes/inhibiteurs de la recapture de la sérotonine

Country Status (1)

Country Link
WO (1) WO2012072665A1 (fr)

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3381009A (en) 1965-12-15 1968-04-30 Acraf Triazole-(4,3-a)-pyridines
US3857845A (en) 1972-10-16 1974-12-31 Acraf 1-{8 3-(4-metrachlorophenyl-1-piperazinyl)-propyl{9 -3,4-diethyl-{66 {11 -1,2,4-triazolin-5-one
US4338317A (en) 1981-03-16 1982-07-06 Mead Johnson & Company Phenoxyethyl-1,2,4,-triazol-3-one antidepressants
US4613600A (en) 1983-09-30 1986-09-23 Mead Johnson & Company Antidepressant 1,2,4-triazolone compounds
WO1993014091A1 (fr) 1992-01-17 1993-07-22 Istituto Ricerca Francesco Angelini S.P.A. Derives alkyles de trazodone influant sur le systeme nerveux central
WO1999011208A1 (fr) 1997-08-28 1999-03-11 Williams C Donald Methode et composition permettant l'administration transdermique d'agents pharmacologiques
US6034085A (en) 1994-11-02 2000-03-07 Bristol-Myers Squibb Co. Salt form of nefazodone for use in extended release formulations
WO2000061129A2 (fr) 1999-04-09 2000-10-19 Sepracor Inc. S-hydroxynefazodone
WO2000061128A2 (fr) 1999-04-09 2000-10-19 Sepracor Inc. Hydroxy-nefazodone r
US6143325A (en) 1998-06-05 2000-11-07 Bristol-Myers Squibb Company Nefazodone dosage form
EP1108722A1 (fr) 1999-12-16 2001-06-20 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. Chlorhydrate de Trazodone et procédé pour sa préparation
US6290986B1 (en) 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US6448404B1 (en) 1998-10-23 2002-09-10 Finaf 92, S.A. Crystalline form of nefazodone and process for the preparation thereof
US6607748B1 (en) 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
WO2005053796A1 (fr) 2003-12-02 2005-06-16 B & B Beheer Nv Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels d4 et 5ht2a,
WO2007048220A2 (fr) 2005-09-09 2007-05-03 Labopharm Inc. Composition de trazodone a administration quotidienne
WO2009016069A2 (fr) 2007-07-31 2009-02-05 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Composition pharmaceutique liquide stable à base de trazodone
WO2009019133A1 (fr) 2007-08-03 2009-02-12 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Trazodone et chlorhydrate de trazodone sous forme purifiée
EP2236138A1 (fr) * 2009-03-30 2010-10-06 PharmaNeuroBoost N.V. Pipampèrone faible dose pour le traitement des troubles de l`anxiété et de l`humeur

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3381009A (en) 1965-12-15 1968-04-30 Acraf Triazole-(4,3-a)-pyridines
US3857845A (en) 1972-10-16 1974-12-31 Acraf 1-{8 3-(4-metrachlorophenyl-1-piperazinyl)-propyl{9 -3,4-diethyl-{66 {11 -1,2,4-triazolin-5-one
US4338317A (en) 1981-03-16 1982-07-06 Mead Johnson & Company Phenoxyethyl-1,2,4,-triazol-3-one antidepressants
US4613600A (en) 1983-09-30 1986-09-23 Mead Johnson & Company Antidepressant 1,2,4-triazolone compounds
WO1993014091A1 (fr) 1992-01-17 1993-07-22 Istituto Ricerca Francesco Angelini S.P.A. Derives alkyles de trazodone influant sur le systeme nerveux central
US6034085A (en) 1994-11-02 2000-03-07 Bristol-Myers Squibb Co. Salt form of nefazodone for use in extended release formulations
US6290986B1 (en) 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
WO1999011208A1 (fr) 1997-08-28 1999-03-11 Williams C Donald Methode et composition permettant l'administration transdermique d'agents pharmacologiques
US6143325A (en) 1998-06-05 2000-11-07 Bristol-Myers Squibb Company Nefazodone dosage form
US6448404B1 (en) 1998-10-23 2002-09-10 Finaf 92, S.A. Crystalline form of nefazodone and process for the preparation thereof
WO2000061129A2 (fr) 1999-04-09 2000-10-19 Sepracor Inc. S-hydroxynefazodone
WO2000061128A2 (fr) 1999-04-09 2000-10-19 Sepracor Inc. Hydroxy-nefazodone r
EP1108722A1 (fr) 1999-12-16 2001-06-20 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. Chlorhydrate de Trazodone et procédé pour sa préparation
US6607748B1 (en) 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
WO2005053796A1 (fr) 2003-12-02 2005-06-16 B & B Beheer Nv Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels d4 et 5ht2a,
WO2007048220A2 (fr) 2005-09-09 2007-05-03 Labopharm Inc. Composition de trazodone a administration quotidienne
WO2007048219A2 (fr) 2005-09-09 2007-05-03 Labopharm Inc. Composition medicamenteuse a liberation prolongee
US7829120B2 (en) 2005-09-09 2010-11-09 Labopharm Inc. Trazodone composition for once a day administration
WO2009016069A2 (fr) 2007-07-31 2009-02-05 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Composition pharmaceutique liquide stable à base de trazodone
WO2009019133A1 (fr) 2007-08-03 2009-02-12 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Trazodone et chlorhydrate de trazodone sous forme purifiée
EP2236138A1 (fr) * 2009-03-30 2010-10-06 PharmaNeuroBoost N.V. Pipampèrone faible dose pour le traitement des troubles de l`anxiété et de l`humeur

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
"ASHP Handbook on Injectable Drugs", 1986, pages: 622 - 630
"DSM-IV", 1993
"Pharmaceutics and Pharmacy Practice", 1982, J.B. LIPPINCOTT COMPANY, pages: 238 - 250
BUNTINX E ET AL: "Preclinical and clinical evidence for the efficacy of pipamperone in augmenting the antidepressant effects of the SSRI citalopram", INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, GB, vol. 11, no. Suppl. 1, 1 July 2008 (2008-07-01), pages 190, XP002531621, ISSN: 1461-1457, [retrieved on 20080904], DOI: 10.1017/S1461145708009462 *
DIEHL, COMPR. PSYCHIATRY, vol. 33, 1992, pages 115 - 120
GRATZ, K. L.; ROEMER, L.: "Annual meeting of the Association for Advancement of Behavior Therapy", November 2001
GROSS, J. J.; MUNOZ, R. F.: "Clinical Psychology: Science and Practice", vol. 2, 1995, pages: 151 - 164
HAMILTON M.: "A rating scale for depression", J NEUROL NEUROSURG PSYCHIATRY, vol. 196023, pages 56 - 62
HOLLANDER E; KORAN LM; GOODMAN WK; GREIST JH; NINAN PT ET AL.: "A double-blind, placebo- controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder", JOURNAL OF CLINICAL PSYCHIATRY, vol. 64, June 2003 (2003-06-01), pages 640 - 647
JOURNAL OF CLINICAL PSYCHIATRY, vol. 65, 2004, pages 405 - 413
JOURNAL OF PSYCHOPATHOLOGY AND BEHAVIORAL ASSESSMENT, vol. 26, no. 1, March 2004 (2004-03-01)
LINEHAN, M. M.: "New York", 1993, THE GUILFORD PRESS
MAREK, PSYCHOPHARMACOLOGY, vol. 109, 1992, pages 2 - 11
MENNIN, D.S.; HEIMBERG, R. G.; TURK, C. L.; FRESCO, D. M., CLINICAL PSYCHOLOGY: SCIENCE AND PRACTICE, vol. 9, 2002, pages 85 - 90
MUNOZZA, CURRENT MEDICAL RESEARCH AND OPINIONS, vol. 22, 2006, pages 1703 - 1713
S. M. STAHL: "Essential Psychopharmacology", 15 June 2000, UNIVERSITY PRESS, article "Newer Antidepressants and Mood Stabilizers"
S. M. STAHL: "Essential Psychopharmacology, Depression and Bipolar Disorders", vol. 151, 15 June 2000, UNIVERSITY PRESS
THASE ET AL., BR. J. PSYCHIATRY, vol. 178, 2001, pages 234 - 241

Similar Documents

Publication Publication Date Title
EP1708790B1 (fr) Utilisation de pipamperone et d'un antagoniste des recepteurs d2 ou d'un antagoniste a la dopamine et a la serotonine pour le traitement de troubles psychotiques
US20050203130A1 (en) Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
AU2003284005B2 (en) Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
EP1541197B1 (fr) Utilisation de pipamperone et d'un SNDRI, SNRI ou SSRI pour le traitement des troubles de l'humeur ou anxieux
US20050119248A1 (en) Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050119249A1 (en) Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2008083442A1 (fr) Procédé pour la formulation de médicaments mixtes contre tdah
US11000519B2 (en) Pridopidine for treating drug induced dyskinesias
ZA200509904B (en) Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight
US20120010242A1 (en) Low dose pipamperone in treating mood disorders
EP2236138A1 (fr) Pipampèrone faible dose pour le traitement des troubles de l`anxiété et de l`humeur
WO2010112530A1 (fr) Traitement de troubles de l'humeur et de l'anxiété à l'aide de la pipampérone et d'une seconde substance active
EP1576985A1 (fr) Utilisation d'antagonistes, d'agonistes partiels ou d'agonistes inverses des recepturs D4 et 5-HT2A
WO2022246405A1 (fr) Procédés de traitement de troubles du système nerveux central par activation des récepteurs muscariniques et d'antipsychotiques
WO2012072665A1 (fr) Compositions comprenant de la pipampérone et des antagonistes/inhibiteurs de la recapture de la sérotonine
CA2461248C (fr) Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a
JP4571645B2 (ja) Ｄ４および５−ｈｔ２ａアンタゴニスト、逆アゴニストまたは部分アゴニストの使用
US20210275512A1 (en) Pridopidine for treating drug induced dyskinesias
Onge et al. Pain associated with diabetic peripheral neuropathy: a review of available treatments
CA2451798C (fr) Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels de d4 et de 5-ht2a
CZ20004067A3 (cs) Nové kombinace léků N.A.R.I.(inhibitory reaktivace noradrenalinu), s výhodou reboxetinu, a pinodolu

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11801634

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11801634

Country of ref document: EP

Kind code of ref document: A1